Up­dat­ed: Mer­ck com­mits up to $610M to buy out pre­clin­i­cal biotech and its neu­rode­gen­er­a­tive dis­ease work

Mer­ck is snap­ping up a pri­vate biotech fo­cused on ge­net­i­cal­ly de­fined neu­rode­gen­er­a­tive dis­or­ders and rare dis­eases, promis­ing to pay $610 mil­lion if every­thing works out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.